"None of these headwinds can be faced without us bending. From my perspective, this move is a response to those changes, and it demonstrates our ability to be able to meet a challenge - it is important because it is going to continue," he told BioPharmaDispatch.
Dennis Bastas on Arrotex and creating the largest company by volume in PBS history
July 11, 2019 Latest NewsBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
Surely this therapy is an example of our system at its absolute worst?
June 28, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Guild says pharmacy a solution as AMA flags ambulance ramping crisis
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News


